 |
 |
|||||||||||||||
 |
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
Intravenous Administration In Combination With Paclitaxel And Carboplatin - United Kingdom In May 2007, Oncolytics announced that it had commenced patient enrolment in a clinical trial in the U.K. using intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin. The primary objective of the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN® when administered in combination with paclitaxel and carboplatin. Secondary objectives include the evaluation of immune response to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity. See related press releases and documents: April 9, 2008 - Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN® and Carboplatin/Paclitaxel Trial May 29, 2007 - Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN®/Paclitaxel and Carboplatin Trial December 22, 2006 - Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN® in Combination with Paclitaxel and Carboplatin |
|
|||||||||||
 |
|
 |